Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases
作者： Stéphane Renaud , Pierre-Emmanuel Falcoz , Mickaël Schaëffer , Dominique Guenot , Benoit Romain
DOI: 10.1038/BJC.2015.327
关键词: Oncology 、 Breast cancer 、 Colorectal cancer 、 Retrospective cohort study 、 Adenocarcinoma 、 Hazard ratio 、 Cohort 、 Internal medicine 、 Lung cancer 、 KRAS 、 Medicine
摘要: Identifying patients who will experience lung cancer recurrence after surgery remains a challenge. We aimed to evaluate whether mutant forms of epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (KRAS) (mEGFR mKRAS) are useful biomarkers in resected non-small cell (NSCLC). retrospectively reviewed data from 841 underwent molecular testing for NSCLC between 2007 2012. mEGFR was observed 103 (12.2%), mKRAS 265 (31.5%). The median overall survival (OS) time (TTR) were significantly lower (OS: 43 months; TTR: 19 months) compared with 67 24 wild-type 55 disease-free (DFS): months). Patients KRAS G12V exhibited worse OS TTR the entire cohort G12V: 26 months vs Cohort: 60 DFS: 15 These results confirmed using multivariate analyses (non-G12V status, hazard ratio (HR): 0.43 (confidence interval: 0.28–0.65), P<0.0001 OS; HR: 0.67 (0.48–0.92), P=0.01 TTR). Risk non-KRAS (HR: 0.01, (0.001–0.08), P<0.0001). may predict early stages NSCLC. higher incidences.
nature.com
sci-hub.se 参考文章(22)
Hidetaka Uramoto, Fumihiro Tanaka, Recurrence after surgery in patients with NSCLC Translational lung cancer research. ,vol. 3, pp. 242- 249 ,(2014) , 10.3978/J.ISSN.2218-6751.2013.12.05
Michèle Beau-Faller, Hélène Blons, Caroline Domerg, Dorota Gajda, Nicolas Richard, Fabienne Escande, Jérôme Solassol, Marc G Denis, Anne Cayre, Isabelle Nanni-Metellus, Sylviane Olschwang, Sarab Lizard, Fabienne Piard, Jean-Luc Pretet, Florence De Fraipont, Ivan Bièche, Patricia De Cremoux, Isabelle Rouquette, Pierre-Paul Bringuier, Jean Mosser, Michèle Legrain, Anne-Claire Voegeli, Patrick Saulnier, Franck Morin, Jean-Pierre Pignon, Gérard Zalcman, Jacques Cadranel, None, A Multicenter Blinded Study Evaluating EGFR and KRAS Mutation Testing Methods in the Clinical Non–Small Cell Lung Cancer Setting—IFCT/ERMETIC2 Project Part 1: Comparison of Testing Methods in 20 French Molecular Genetic National Cancer Institute Platforms The Journal of Molecular Diagnostics. ,vol. 16, pp. 45- 55 ,(2014) , 10.1016/J.JMOLDX.2013.07.009
Sandra P. D’Angelo, Yelena Y. Janjigian, Nicholas Ahye, Gregory J. Riely, Jamie E. Chaft, Camelia S. Sima, Ronglai Shen, Junting Zheng, Joseph Dycoco, Mark G. Kris, Maureen F. Zakowski, Marc Ladanyi, Valerie Rusch, Christopher G. Azzoli, Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib Journal of Thoracic Oncology. ,vol. 7, pp. 1815- 1822 ,(2012) , 10.1097/JTO.0B013E31826BB7B2
Jenifer L. Marks, Stephen Broderick, Qin Zhou, Dhananjay Chitale, Allan R. Li, Maureen F. Zakowski, Mark G. Kris, Valerie W. Rusch, Christopher G. Azzoli, Venkatraman E. Seshan, Marc Ladanyi, William Pao, Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma Journal of Thoracic Oncology. ,vol. 3, pp. 111- 116 ,(2008) , 10.1097/JTO.0B013E318160C607
Daquan Meng, Mingli Yuan, Xiaojuan Li, Lijun Chen, Jie Yang, Xin Zhao, Wanli Ma, Jianbao Xin, Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer. ,vol. 81, pp. 1- 10 ,(2013) , 10.1016/J.LUNGCAN.2013.03.019
Mary E. Charlson, Peter Pompei, Kathy L. Ales, C.Ronald MacKenzie, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation☆ Journal of Chronic Diseases. ,vol. 40, pp. 373- 383 ,(1987) , 10.1016/0021-9681(87)90171-8
Patricia Alamo, Alberto Gallardo, Federica Di Nicolantonio, Miguel Angel Pavón, Isolda Casanova, Manuel Trias, María Antonia Mangues, Antonio Lopez‐Pousa, Antonio Villaverde, Esther Vázquez, Alberto Bardelli, María Virtudes Céspedes, Ramón Mangues, Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model The FASEB Journal. ,vol. 29, pp. 464- 476 ,(2015) , 10.1096/FJ.14-262303
Benjamin Izar, Haiyu Zhou, Rebecca S. Heist, Christopher G. Azzoli, Alona Muzikansky, Emily E.F. Scribner, Lindsay A. Bernardo, Dora Dias-Santagata, Anthony J. Iafrate, Michael Lanuti, The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Journal of Thoracic Oncology. ,vol. 9, pp. 1363- 1369 ,(2014) , 10.1097/JTO.0000000000000266
Yelena Y Janjigian, Bernard J Park, Maureen F Zakowski, Marc Ladanyi, William Pao, Sandra P D'Angelo, Mark G Kris, Ronglai Shen, Junting Zheng, Christopher G Azzoli, None, Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Journal of Thoracic Oncology. ,vol. 6, pp. 569- 575 ,(2011) , 10.1097/JTO.0B013E318202BFFE
Ernest Nadal, Guoan Chen, John R. Prensner, Hiroe Shiratsuchi, Christine Sam, Lili Zhao, Gregory P. Kalemkerian, Dean Brenner, Jules Lin, Rishindra M. Reddy, Andrew C. Chang, Gabriel Capellà, Felipe Cardenal, David G. Beer, Nithya Ramnath, KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma Journal of Thoracic Oncology. ,vol. 9, pp. 1513- 1522 ,(2014) , 10.1097/JTO.0000000000000305